Skip to main content
Top
Published in: Abdominal Radiology 7/2015

01-10-2015

Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase

Authors: Giuseppe Mamone, Gianluca Marrone, Settimo Caruso, Vincenzo Carollo, Giovanni Gentile, Francesca Crino’, Mariapina Milazzo, Angelo Luca

Published in: Abdominal Radiology | Issue 7/2015

Login to get access

Abstract

Purpose: To describe the Gd-BOPTA MRI findings of intrahepatic mass-forming type cholangiocarcinomas (IMCs), with emphasis on the hepatobiliary phase (HBP). Methods: We reviewed retrospectively 29 IMC patients who underwent Gd-BOPTA-MRI between June, 2004 and June, 2014. Images were acquired prior to, and after, administration of 15–20 mL of Gd-BOPTA in the dynamic phase (arterial phase, portal venous phase, and 3–5 min phase), 10–15-min late phase, and 2–3 h HBP phase. Results: In the dynamic phase, 27 (93%) lesions showed a peripheral rim-like enhancement in the arterial and portal venous phases, followed by progressive filling-in on the delayed images. In 14 (56%) cases, a hypointense peripheral rim was identified in the 10–15-min late phase, delineating a target pattern. In the HBP, the cholangiocarcinoma showed a diffuse, mainly central and inhomogeneous enhancement (cloud of enhancement) in 28 (96%) patients; in 23 (79%) cases, there was an association between cloud appearance and a hypointense peripheral rim, showing a target pattern. Conclusions: Gd-BOPTA MRI pattern of IMC on dynamic study is similar to that of conventional extracellular agents, that is peripheral enhancement with progressive and concentric filling of contrast material on delayed phases. At 10–15 min delayed phases, IMC shows often a peripheral hypointense rim consistent with a target appearance. In the HBP, due to progressive central enhancement (cloud) and peripheral hypointense rim, an higher number of tumors show a target appearance; this pattern is not specific and would also be expected to be seen in metastases from adenocarcinoma.
Literature
1.
3.
go back to reference Tanimoto A, Lee JM, Murakami T, et al. (2009) Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 19(Suppl 5):S975–S989CrossRefPubMed Tanimoto A, Lee JM, Murakami T, et al. (2009) Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 19(Suppl 5):S975–S989CrossRefPubMed
4.
go back to reference Jeon TY, Kim SH, Lee WJ, Lim HK (2010) The value of gadobenatedimeglumine–enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma. Abdom Imaging 35:337–345CrossRefPubMed Jeon TY, Kim SH, Lee WJ, Lim HK (2010) The value of gadobenatedimeglumine–enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma. Abdom Imaging 35:337–345CrossRefPubMed
5.
go back to reference Kim YK, Lee JM, Kim CS (2004) Gadobenatedimeglumine–enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13CrossRefPubMed Kim YK, Lee JM, Kim CS (2004) Gadobenatedimeglumine–enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13CrossRefPubMed
6.
go back to reference Gabata T, Matusi O, Kadoya M, et al. (1998) Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 23:309–313CrossRefPubMed Gabata T, Matusi O, Kadoya M, et al. (1998) Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 23:309–313CrossRefPubMed
7.
go back to reference Grazioli L, Bondioni MP, Faccioli N, et al. (2010) Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenatedimeglumine. J Gastrointest Cancer 41(4):221–232CrossRefPubMed Grazioli L, Bondioni MP, Faccioli N, et al. (2010) Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenatedimeglumine. J Gastrointest Cancer 41(4):221–232CrossRefPubMed
8.
go back to reference Hwang HS, Kim SH, Jeon TY, et al. (2009) Hypointense hepatic lesions depicted on gadobenatedimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol 10:294–302PubMedCentralCrossRefPubMed Hwang HS, Kim SH, Jeon TY, et al. (2009) Hypointense hepatic lesions depicted on gadobenatedimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol 10:294–302PubMedCentralCrossRefPubMed
9.
go back to reference Schneider G, Altmeyer K, Kirchin MA, et al. (2007) Evaluation of a novel time-efficient protocol for gadobenatedimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol 42:105–115CrossRefPubMed Schneider G, Altmeyer K, Kirchin MA, et al. (2007) Evaluation of a novel time-efficient protocol for gadobenatedimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol 42:105–115CrossRefPubMed
10.
go back to reference Hamrick-Turner J, Abbitt PL, Ros PR (1992) Intrahepatic cholangiocarcinoma: MR appearance. AJR 158:77–79CrossRefPubMed Hamrick-Turner J, Abbitt PL, Ros PR (1992) Intrahepatic cholangiocarcinoma: MR appearance. AJR 158:77–79CrossRefPubMed
11.
go back to reference Vilgrain V, Van Beers BE, Flejou JF, et al. (1997) Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 21(1):59–65CrossRefPubMed Vilgrain V, Van Beers BE, Flejou JF, et al. (1997) Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 21(1):59–65CrossRefPubMed
12.
go back to reference Ros PR, Buck JL, Goodman ZD, ViamonteRos AM, Olmsted WW (1988) Intrahepatic cholangiocarcinoma: radiologic-pathologic correlation. Radiology 167:689–693CrossRefPubMed Ros PR, Buck JL, Goodman ZD, ViamonteRos AM, Olmsted WW (1988) Intrahepatic cholangiocarcinoma: radiologic-pathologic correlation. Radiology 167:689–693CrossRefPubMed
13.
go back to reference Maetani Y, Itoh K, Watanabe C, et al. (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR 176:1499–1507CrossRefPubMed Maetani Y, Itoh K, Watanabe C, et al. (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR 176:1499–1507CrossRefPubMed
14.
go back to reference Yoshida Y, Imai Y, Murakami T, et al. (1999) Intrahepaticcholangiocarcinoma with marked hypervascularity. Abdom Imaging 24:66–68CrossRefPubMed Yoshida Y, Imai Y, Murakami T, et al. (1999) Intrahepaticcholangiocarcinoma with marked hypervascularity. Abdom Imaging 24:66–68CrossRefPubMed
15.
go back to reference Yoshikawa J, Matsui O, Kadoya M, et al. (1992) Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. J Comput Assist Tomogr 16(2):206–211CrossRefPubMed Yoshikawa J, Matsui O, Kadoya M, et al. (1992) Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. J Comput Assist Tomogr 16(2):206–211CrossRefPubMed
16.
go back to reference Kim SH, Lee CH, Kim BH, et al. (2012) Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyldiethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 36(6):704–709CrossRefPubMed Kim SH, Lee CH, Kim BH, et al. (2012) Typical and atypical imaging findings of intrahepatic cholangiocarcinoma using gadolinium ethoxybenzyldiethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 36(6):704–709CrossRefPubMed
17.
go back to reference Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M (1999) The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of “scirrhous-type” and “nonscirrhous-type” growth. Am J Surg Pathol 23:892–902CrossRefPubMed Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M (1999) The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of “scirrhous-type” and “nonscirrhous-type” growth. Am J Surg Pathol 23:892–902CrossRefPubMed
18.
go back to reference Lacomis JM, Baron RL, Oliver JH 3rd, Nalesnik MA, Federle MP (1997) Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 203(1):98–104CrossRefPubMed Lacomis JM, Baron RL, Oliver JH 3rd, Nalesnik MA, Federle MP (1997) Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 203(1):98–104CrossRefPubMed
19.
go back to reference Mahfouz AE, Hamm B, Wolf KJ (1994) Peripheral washout: a sign of malignancy on dynamic gadolinium enhanced MR images of focal liver lesions. Radiology 190:49–52CrossRefPubMed Mahfouz AE, Hamm B, Wolf KJ (1994) Peripheral washout: a sign of malignancy on dynamic gadolinium enhanced MR images of focal liver lesions. Radiology 190:49–52CrossRefPubMed
20.
go back to reference Jeong HT, Kim MJ, Chung YE, et al. (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201(4):W603–W611CrossRefPubMed Jeong HT, Kim MJ, Chung YE, et al. (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201(4):W603–W611CrossRefPubMed
21.
go back to reference Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264(3):751–760CrossRefPubMed Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264(3):751–760CrossRefPubMed
22.
go back to reference Worawattanakul S, Semelka RC, Noone TC, et al. (1998) Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. Magn Reson Imaging 16(9):993–1003CrossRefPubMed Worawattanakul S, Semelka RC, Noone TC, et al. (1998) Cholangiocarcinoma: spectrum of appearances on MR images using current techniques. Magn Reson Imaging 16(9):993–1003CrossRefPubMed
23.
go back to reference Schlund JF, Semelka RC, Kettritz U, et al. (1996) Correlation of perfusion abnormalities on CTAP and immediate postintravenous gadolinium-enhanced gradient echo MRI. Abdom Imaging 21:49–52CrossRefPubMed Schlund JF, Semelka RC, Kettritz U, et al. (1996) Correlation of perfusion abnormalities on CTAP and immediate postintravenous gadolinium-enhanced gradient echo MRI. Abdom Imaging 21:49–52CrossRefPubMed
24.
go back to reference Soyer P, Bluemke DA, Vissuzaine C, et al. (1994) CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR 162:1119–1122CrossRefPubMed Soyer P, Bluemke DA, Vissuzaine C, et al. (1994) CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR 162:1119–1122CrossRefPubMed
Metadata
Title
Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase
Authors
Giuseppe Mamone
Gianluca Marrone
Settimo Caruso
Vincenzo Carollo
Giovanni Gentile
Francesca Crino’
Mariapina Milazzo
Angelo Luca
Publication date
01-10-2015
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2015
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0445-5

Other articles of this Issue 7/2015

Abdominal Radiology 7/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.